Literature DB >> 24535168

Prevention: targeted therapy-anastrozole prevents breast cancer.

Powel Brown1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24535168     DOI： 10.1038/nrclinonc.2014.17

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Exemestane for breast-cancer prevention in postmenopausal women.

Authors:  Paul E Goss; James N Ingle; José E Alés-Martínez; Angela M Cheung; Rowan T Chlebowski; Jean Wactawski-Wende; Anne McTiernan; John Robbins; Karen C Johnson; Lisa W Martin; Eric Winquist; Gloria E Sarto; Judy E Garber; Carol J Fabian; Pascal Pujol; Elizabeth Maunsell; Patricia Farmer; Karen A Gelmon; Dongsheng Tu; Harriet Richardson
Journal:  N Engl J Med       Date:  2011-06-04       Impact factor: 91.245

2.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  JAMA       Date:  2006-06-05       Impact factor: 56.272

3.  Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.

Authors:  Andrea Z LaCroix; Trevor Powles; C Kent Osborne; Kevin Wolter; John R Thompson; David D Thompson; D Craig Allred; Róisín Armstrong; Steve R Cummings; Richard Eastell; Kristine E Ensrud; Paul Goss; Andrew Lee; Patrick Neven; David M Reid; Madelyn Curto; Slobodan Vukicevic
Journal:  J Natl Cancer Inst       Date:  2010-11-04       Impact factor: 13.506

4.  Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.

Authors:  N Lynn Henry; Faouzi Azzouz; Zereunesay Desta; Lang Li; Anne T Nguyen; Suzanne Lemler; Jill Hayden; Karineh Tarpinian; Elizabeth Yakim; David A Flockhart; Vered Stearns; Daniel F Hayes; Anna Maria Storniolo
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

5.  Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  Cancer Prev Res (Phila)       Date:  2010-04-19

6.  Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene.

Authors:  Trevor J Powles; Susan J Diem; Carol J Fabian; Patrick Neven; D Lawrence Wickerham; David A Cox; David Muram; Donato Agnusdei; Sherie A Dowsett; Messan Amewou-Atisso; Steven R Cummings
Journal:  Breast Cancer Res Treat       Date:  2012-04-08       Impact factor: 4.872

7.  Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.

Authors:  L C Hartmann; D J Schaid; J E Woods; T P Crotty; J L Myers; P G Arnold; P M Petty; T A Sellers; J L Johnson; S K McDonnell; M H Frost; R B Jenkins
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

8.  Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.

Authors:  Jack Cuzick; Ivana Sestak; John F Forbes; Mitch Dowsett; Jill Knox; Simon Cawthorn; Christobel Saunders; Nicola Roche; Robert E Mansel; Gunter von Minckwitz; Bernardo Bonanni; Tiina Palva; Anthony Howell
Journal:  Lancet       Date:  2013-12-12       Impact factor: 79.321

Review 9.  Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.

Authors:  Jack Cuzick; Ivana Sestak; Bernardo Bonanni; Joseph P Costantino; Steve Cummings; Andrea DeCensi; Mitch Dowsett; John F Forbes; Leslie Ford; Andrea Z LaCroix; John Mershon; Bruce H Mitlak; Trevor Powles; Umberto Veronesi; Victor Vogel; D Lawrence Wickerham
Journal:  Lancet       Date:  2013-04-30       Impact factor: 79.321

Review 10.  Targeted therapy for breast cancer prevention.

Authors:  Petra den Hollander; Michelle I Savage; Powel H Brown
Journal:  Front Oncol       Date:  2013-09-23       Impact factor: 6.244
  10 in total
  5 in total

1.  Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes.

Authors:  Wen Bu; Zhenyu Liu; Weiyu Jiang; Chandandeep Nagi; Shixia Huang; Dean P Edwards; Eunji Jo; Qianxing Mo; Chad J Creighton; Susan G Hilsenbeck; Andrew D Leavitt; Michael T Lewis; Stephen T C Wong; Yi Li
Journal:  Cancer Res       Date:  2018-11-06       Impact factor: 12.701

2.  Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer.

Authors:  Adelaide Young; Wen Bu; Weiyu Jiang; Amy Ku; Jyoti Kapali; Sagar Dhamne; Lan Qin; Susan G Hilsenbeck; Yi-Chieh Nancy Du; Yi Li
Journal:  Cancer Prev Res (Phila)       Date:  2021-10-19

Review 3.  Risk determination and prevention of breast cancer.

Authors:  Anthony Howell; Annie S Anderson; Robert B Clarke; Stephen W Duffy; D Gareth Evans; Montserat Garcia-Closas; Andy J Gescher; Timothy J Key; John M Saxton; Michelle N Harvie
Journal:  Breast Cancer Res       Date:  2014-09-28       Impact factor: 6.466

Review 4.  Cancer prevention as part of precision medicine: 'plenty to be done'.

Authors:  Bernard W Stewart; Freddie Bray; David Forman; Hiroko Ohgaki; Kurt Straif; Andreas Ullrich; Christopher P Wild
Journal:  Carcinogenesis       Date:  2015-11-20       Impact factor: 4.944

5.  Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions.

Authors:  A N Johnston; W Bu; S Hein; S Garcia; L Camacho; L Xue; L Qin; C Nagi; S G Hilsenbeck; J Kapali; K Podsypanina; J Nangia; Y Li
Journal:  Breast Cancer Res       Date:  2018-05-19       Impact factor: 6.466
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.